Form 4 for TRVI Trevi Therapeutics, Inc.
Accepted 2025-01-10 00:00:00 ET · period of report 2025-01-07 · accession 0000950170-25-004164 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-01-10 | 2025-01-07+ | TRVI | Delfini Lisa | CFO | M - OptEx | $0.51 | +6,000 | 59.7K | +11% | +$3,060 |
| DM | 2025-01-10 | 2025-01-07+ | TRVI | Delfini Lisa | CFO | M - OptEx | $0.00 | -6,000 | 47.1K | -11% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-08 | M | A | 5,000 | $0.51 | 64,660 | D | — | — | |
| 2 | Common | Common Stock | 2025-01-07 | M | A | 1,000 | $0.51 | 59,660 | D | — | — | (F1) Includes 5,381 shares purchased through the Issuer's employee stock purchase plan. |
| 3 | Derivative | Stock Option (right to buy) | 2025-01-08 | M | D | 5,000 | $0.00 | 42,125 | D | $0.51 · — to 2032-02-10 | 5,000 Common Stock | (F2) This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026. |
| 4 | Derivative | Stock Option (right to buy) | 2025-01-07 | M | D | 1,000 | $0.00 | 47,125 | D | $0.51 · — to 2032-02-10 | 1,000 Common Stock | (F2) This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026. |